News & Insights

  • Clear

Boston Scientific Agrees to Pay $188.6 Million in Multistate Surgical Mesh Settlement

A bipartisan group of 48 AGs, led by former California AG Xavier Becerra and Washington AG Bob Ferguson, reached a settlement with Boston Scientific Corporation to resolve allegations that it falsely and deceptively marketed its surgical mesh products for women in violation of the settling jurisdictions’ consumer protection laws. The states’ complaints alleged that Boston…

Read More

Opioid Giant Mallinckrodt Reportedly Agrees to $1.6 Billion Global Settlement Framework

47 AGs and thousands of municipalities reportedly reached a global settlement framework with opioid manufacturer Mallinckrodt PLC and related entities (collectively, “Mallinckrodt”) to resolve allegations that Mallinckrodt engaged in deceptive business and marketing practices, misrepresented the risks and marketed off-label uses of prescription opioids, and paid illegal kickbacks.

Read More

Hawaii Court Imposes $834 Million Judgment on Pharmaceutical Companies for Plavix

Hawaii AG Clare Connors obtained a judgment against pharmaceutical company Bristol-Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi and related individuals (collectively “BMS”) after a circuit court found that BMS used deceptive tactics and false advertising to market the blood-thinning drug Plavix in violation of Hawaii’s Unfair and Deceptive Acts or Practices…

Read More

Bipartisan Group of Attorneys General Urge Federal Government to Enforce Mandated Drug Discounts

A bipartisan group of 29 AGs, led by California AG Xavier Becerra, Connecticut AG William Tong, Kansas AG Derek Schmidt, and Nebraska AG Doug Peterson, sent a letter to the U.S. Department of Health & Human Services (“HHS”) Secretary Alex Azar regarding enforcement of the 340B Drug Pricing Program, which requires pharmaceutical companies, as a condition of coverage by Medicaid and Medicare Part B, to enter into Pharmaceutical Pricing Agreements (“PPAs”) with HHS that obligate them to offer each covered medication below an applicable ceiling price to healthcare providers serving uninsured and low-income patients.

Read More

Supreme Court Sides with States’ Right to Regulate Pharmacy Benefit Managers Reimbursement Rates

Arkansas AG Leslie Rutledge, obtained a ruling from the U.S. Supreme Court in Rutledge v. Pharmaceutical Care Management Association, 18-540, upholding Arkansas’s right to regulate the prices at which pharmacy benefit managers (“PMBs”) reimburse pharmacies for drugs covered by prescription-drug plans. A PBM challenged the Arkansas law that regulated PBM reimbursement rates (“Act 900”), arguing that it was preempted by the Employee Retirement Income Security Act (“ERISA”), and the U.S. Court of Appeals for the Eighth Circuit agreed. AG Rutledge appealed.

Read More